Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment
暂无分享,去创建一个
D. Mohr | D. Goodkin | D E Goodkin | D C Mohr | C Griffin | C. Griffin | W Likosk | N Gatto | L K Neilley | B Stiebling | L. Neilley | N. Gatto | W. Likosk | B. Stiebling | D. Mohr
[1] Jeffrey A. Cohen,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.
[2] D. Goodin,et al. Side-effect profile of interferon beta 1-B , 1995, Journal of Neuroimmunology.
[3] D. Goodkin. Interferon beta treatment for multiple sclerosis: persisting questions , 1996, Multiple sclerosis.
[4] M K O'Brien,et al. Adherence to Medication Regimens: Updating a Complex Medical Issue , 1992, Medical care review.
[5] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[6] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[7] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[8] D. Goodkin. Interferon-beta-1b , 1994, The Lancet.
[9] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.